Data set from Bernardini A, Camporeale A, Pieroni M, Pieruzzi F, Figliozzi S, Lusardi P, Spada M, Mignani R, Burlina A, Carubbi F, Battaglia Y, Graziani F, Pica S, Tondi L, Chow K, Boveri S, Olivotto I, Lombardi M. Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy. JACC Cardiovasc Imaging. 2020 Oct;13(10):2262-2264. doi: 10.1016/j.jcmg.2020.05.011. Epub 2020 Jun 17. PMID: 32563647.

Data set from the article Bernardini A, Camporeale A, Pieroni M, Pieruzzi F, Figliozzi S, Lusardi P, Spada M, Mignani R, Burlina A, Carubbi F, Battaglia Y, Graziani F, Pica S, Tondi L, Chow K, Boveri S, Olivotto I, Lombardi M. Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy. JACC Cardiovasc Imaging. 2020 Oct;13(10):2262-2264. doi: 10.1016/j.jcmg.2020.05.011. Epub 2020 Jun 17. PMID: 32563647.

Brief introduction

Anderson-Fabry disease (AFD) cardiomyopathy is characterized by glycosphingolipid (Gb3) storage in all cellular components, with consequent left ventricular hypertrophy (LVH). Gb3 accumulation also involves atrial myocytes (1), ultimately leading to left atrial (LA) enlargement and reduced atrial compliance. Cardiac magnetic resonance (CMR) plays an important role in the assessment of the severity of Fabry cardiomyopathy. CMR feature tracking (CMR-FT) specifically allows the assessment of myocardial strain from cine images